Lipid-based polymeric nanoparticles are the highly popular carrier systems for cancer drug
therapy. But presently, detailed investigations have revealed their flaws as drug delivery …

Conventional chemotherapeutic approaches in cancer therapy such as surgery,
chemotherapy, and radiotherapy have several disadvantages due to their nontargeted …

Nanostructured lipid carriers (NLCs) are modified solid lipid nanoparticles (SLNs) that retain
the characteristics of the SLN, improve drug stability and loading capacity, and prevent drug …

Lipid polymer hybrid nanoparticles (LPHN) are novel systems which are potentially
emerging in the era of nano-medicine. They are core-shell nanostructures which comprise of …

Erlotinib (ERT), oral administration agents, is one of the most pivotal targeted drugs in the
treatment of non‐small cell lung cancer (NSCLC); however, its poor solubility, low oral …

Solid lipid nanoparticle (SLN), nanostructured lipid carriers (NLC) and hybrid nanoparticles,
have gained increasing interest as drug delivery systems because of their potential to load …

Lung cancer is the foremost reason of death from cancers with broad genetic and epigenetic
diversity. Various strategies are clinically available for diagnosis and treatment of lung …

Abstract Poly-ε-caprolactone (PCL) has been the subject of extensive research in the past
few years. It is widely explored in drug delivery, where the development of nanomedicines …

Today, the advanced drug delivery systems have been focused on targeted drug delivery
fields. The novel drug delivery is involved with the improvement of the capacity of drug …

Polymer–lipid hybrid nanoparticles (PLN) are an emerging nanocarrier platform made from
building blocks of polymers and lipids. PLN integrate the advantages of biomimetic lipid …